A novel and convenient method was established for the prediction of in vivo metabolic clearance in human liver. The present method applied the in vitro-in vivo extrapolation paradigm previously established in rats to the in vitro data obtained from cryopreserved human hepatocytes. Predicted hepatic availability and clearance were compared with the reported oral bioavailability and plasma clearance in humans for 14 clinically used drugs (naloxone, buspirone, verapamil, lidocaine, imipramine, metoprolol, timolol, antipyrine, diazepam, quinidine, caffeine, propranolol, diclofenac, and phenacetin). A large interindividual variation was observed in the intrinsic metabolic clearance among separate cryopreserved preparations from different subjects. The prediction generally resulted in a marked underestimation when the biologically based scaling (cells/kg) from pooled preparation of two selected lots, which were 3-to 4-fold larger than the biologically based scaling factor. These data suggested that the calibration of inherent interindividual variation of metabolic activities among different cryopreserved preparations of human hepatocytes to obtain the empirical scaling factor, which is applicable only to the preparation used, was an essential step for more reliable and quantitative prediction of in vivo metabolic activity in humans.
Hepatic clearance for the metabolism of compounds kinetically consists of two major determinants: intrinsic (metabolic) clearance of the unbound compound and unbound fraction of compound in the blood (or plasma when corrected by the blood-to-plasma partition). Generally, the intrinsic clearance for the unbound compound is measured in vitro by the incubation of isolated hepatocytes or subcellular fractions such as S-9 and microsomes in the protein-free medium. The in vitro metabolic parameters thus obtained are extrapolated by using anatomical parameters such as cell numbers and protein content in the intact liver for the prediction of in vivo metabolic activity (Houston and Carlile, 1997; Iwatsubo et al., 1997; Obach, 1999) . Separate experiments necessarily are further carried out to measure the unbound fraction in the plasma. Many technical problems including adsorption of compounds to the apparatus during the equilibrium dialysis and ultra-filtration often hamper the accuracy of the evaluated values (Bertilsson et al., 1979; Desoye, 1988) . To improve the accuracy and avoid complexity for predicting in vivo metabolic clearance from in vitro experiments, we have recently developed a novel and convenient in vitro method for predicting in vivo metabolic clearance by using freshly isolated rat hepatocytes suspended in rat serum (Shibata et al., 2000) . Oral bioavailability and hepatic clearance for 16 widely used compounds were well predicted directly from the in vitro metabolic clearance values obtained from a single incubation without separate evaluation of unbound fraction in the plasma. The purposes of the present study were to 1) determine whether the same methodology was applicable to the prediction of in vivo metabolic activity in humans by using cryopreserved human hepatocytes and 2) establish the in vitro-in vivo scaling-up paradigm to calibrate the interindividual variation of the metabolic activities among cryopreserved preparations from different subjects for more reliable and quantitative prediction in humans.
Materials and Methods
Naloxone and lidocaine were purchased from Nacalai Tesque (Kyoto, Japan) and Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan), respectively. Buspirone, metoprolol, phenacetin, propranolol, quinidine, timolol, and verapamil were obtained from Sigma-Aldrich (St. Louis, MO). Antipyrine, caffeine, diazepam, diclofenac, and imipramine were obtained from Wako Pure Chemical Industries (Osaka, Japan). Blood was collected from three healthy male volunteers aged 25 to 40 years old and allowed to coagulate for 3 h at room temperature. The blood was later centrifuged (15 min, 1800g) to obtain serum. The serum was stored at Ϫ80°C until use. The pH of human serum was adjusted to 7.4 at 37°C by adding 1N-HCl solution before use. Cryopreserved human hepatocytes (lot numbers 56, 57, 64, 70, 73, 83, 97, 100, 106, and 120) were purchased from In Vitro Technologies, Inc. (Baltimore, MD). Cell viability was assessed using the 0.4% trypan blue exclusion test, and the count of living cells was started 5 min after mixing the pigment. Cell viabilities were between 45 and 60%. Hepatocytes were resuspended in 100% human serum at an ice-cold temperature at the following densities: 1 ϫ 10 6 cells/ml for naloxone, buspirone, verapamil, lidocaine, imipramine, metoprolol, and timolol; 2 ϫ 10 6 cells/ml for quinidine, caffeine, propranolol, diclofenac, and phenacetin; and 5 ϫ 10 6 cells/ml for antipyrine and diazepam. Suspensions of hepatocytes (370 l) were pipetted into 1.5-ml tubes, and an aliquot (3.7 l) of 100 M compound in a water (or 50% CH 3 CN for quinidine and phenacetin) was added to obtain the final concentration of 1 M (or 50 M for antipyrine and 10 M for caffeine). Each sample (50 l) was transferred to two 96-well plates with flat bottoms (n ϭ 3), each of which was used for the incubation or for the control. Ninety-six well plates were incubated at 37°C with shaking at 150 rpm under 95% O 2 /5% CO 2 in the water bath incubator. After the onset of incubation, the plates were placed on ice at the designated time point, and the reaction was terminated by the addition of a 150-l ice-cold ethanol solution containing the internal standard (no internal standard for antipyrine and caffeine). The sample was centrifuged (10,000g ϫ 10 min), and the amount of compound remaining in the supernatant was measured by HPLC 1 -UV (antipyrine and caffeine) or LC-MS/MS (others) as described below.
Antipyrine was measured at 254 nm by the Alliance 2690 -2487 HPLC-UV system (Waters Corp., Milford, MA) that was connected to Inertsil ODS-3 4.6 ϫ 250 mm (GL-Sciences, Tokyo, Japan), which acted as an analytical column. The HPLC method involved the isocratic elution with acetonitrile/ water (25:75) containing 10 mM ammonium acetate at the flow rate of 1 ml/min. The retention time of antipyrine was 7 min. Caffeine was measured by the UV wavelength of 280 nm at a flow rate of 1 ml/min of acetonitrile/water (10:90) containing 0.1% trifluoroacetic acid. The retention time of caffeine was 16 min. Other compounds were measured by the Alliance HT 2790 HPLC (Waters Corp.), PU-1580 HPLC pump (Jasco, Tokyo, Japan), NANOSPACE SI-2 switching valves (Shiseido, Osaka, Japan), and API-3000 LC-MS/MS detector (PerkinElmerSciex Instruments, Boston, MA) with a turbo ionspray interface. Multiple reaction monitoring of positive-ion mode was used for all analyses. Analytical methods including the selection of ions and parameters for multiple reaction monitoring were automatically obtained for each compound by the application software, Analyst (PerkinElmerSciex Instruments). Mass number of molecular ions and product ions for each compound was identified as follows (molecular Ͼ product): naloxone 328. A fast-gradient condition using two switching valves and pumps (3.5 min/cycle) was used for the analysis. Capcell Pak UG-120 4.0 ϫ 10 mm (Shiseido) was used as an analytical column, and the flow rate of 1 ml/min of acetonitrile/water (10:90) containing 10 mM ammonium acetate was the initial condition used. After the injection of a sample (5 l), the ratio of acetonitrile/water was changed to 90:10 linearly for 1 min and maintained for the next 0.5 min. The column was then washed with acetonitrile/water (90:10) containing 10 mM ammonium acetate at a back flow rate of 1 ml/min. The effluent was split with 0.2 ml/min, and only the effluent from 0.5 to 1.5 min after the injection was introduced into the LC-MS/MS detector. Modified conditions were used for metoprolol, timolol, and phenacetin. In the case of metoprolol and timolol, Symmetry Shield RP18/3.5 M 2.1 ϫ 10 mm (Waters Corp.) was used as the analytical column.
After the injection of a sample, the ratio of acetonitrile/water was changed linearly to 66:34 for 1.4 min, and the effluent from 0.4 to 1.5 min after the injection was introduced into the LC-MS/MS detector. In the case of phenacetin, Inertsil ODS-3 2.1 ϫ 150 mm (GL-Sciences) was used as the analytical column. After the injection of a sample, the ratio of acetonitrile/water was changed linearly to 34:66 for 3 min and then changed linearly to 90:10 for the next 2 min. The effluent from 0.5 to 5 min after the injection was introduced into the LC-MS/MS detector. Diazepam was commonly used as the internal standard. When diazepam was the analyte, quinidine was used as the internal standard.
For standard compounds, the following assumptions were reasonably applied to the prediction, 1) the hepatic metabolism is the major route of elimination, 2) all metabolic enzymes in the cryopreserved preparation of human hepatocytes remain active comparably to in vivo, and 3) the absorption is complete for all standard compounds. The in vitro intrinsic clearance (CL int, in vitro ) was calculated from the following equation by using cell density (D), incubation time (T, 120 min for the calculation of CL int, in vitro ), and the ratio (R) of unchanged compound concentration at time T to that at time 0 when the unbound drug concentration was much lower than its K m value (Shibata et al., 2000) ; CL int, in vitro ϭ (Ϫlog e R)/(D ϫ T). To extrapolate the in vitro clearance to the in vivo value, the empirical scaling factor (average SF 70ϩ73 ) for the optimized cryopreserved preparation pooled from equal volumes of human hepatocytes (lot numbers 70 and 73) was calculated according to the method described under the Results section. The value of average SF 70 ϩ 73 was 10.8 ϫ 10 9 cells/kg of body weight and used for the extrapolation as follows: CL H, int, in vitro, 70ϩ73 ϭ CL int, in vitro, 70ϩ73 ϫ average SF 70ϩ73 where CL H, int, in vitro, 70ϩ73 and CL int, in vitro, 70ϩ73 represent the in vitro hepatic intrinsic clearance and in vitro intrinsic clearance, respectively, measured in the pooled preparation of lot 70 and 73. We chose the dispersion model as a liver model because a good predictability of hepatic availability (F H ) for high clearance drugs was previously reported (Iwatsubo et al., 1997) . The hepatic clearance (CL H, predicted, 70ϩ73 ) was predicted from the obtained in vitro hepatic intrinsic clearance (CL H, int, in vitro, 70ϩ73 ) by using the following equation (eq. 1) with the dispersion model (Iwatsubo et al., 1997) ;
. In these equations, the liver blood flow rate (Q H ) and dispersion number (D N ) for humans were assumed to be 20.7 ml/min/kg (Davies and Morris, 1993) and 0.17 (Roberts and Rowland, 1986) , respectively. The blood-to-plasma concentration ratio (R B ) was used as reported or assumed to be unity if the value was not available.
Results
Tables 1 and 2 summarize the pharmacokinetic profiles in humans and the results of extrapolations from the in vitro data for the standard compounds tested in the present study. These compounds were chosen to represent a wide range of oral bioavailability (2-96%) and plasma clearance (0.3-28.3 ml/min/kg). These standard compounds are reported to have complete absorption, negligible urinary excretion (Ͻ20% of dose), and the major route of elimination by hepatic metabolism. Therefore, it was reasonably assumed that the in vivo plasma clearance (CL P, in vivo ) and oral bioavailability (F PO, in vivo ) are equal to the hepatic metabolic clearance (CL H ) and F H , respectively. In vivo values for hepatic intrinsic clearance (CL H, int, in vivo ) of standard compounds were calculated from F PO, in vivo by the dispersion model using the iterative calculation method (Goal Seek method in Microsoft Excel). To calculate empirical scaling factor from the comparison of in vivo and in vitro hepatic intrinsic clearance, CL int, in vitro values were evaluated in the cryopreserved preparations of human hepatocytes obtained from 10 different subjects. An approximately 3-to 5-fold variation in the CL int, in vitro was observed 1 Abbreviations used are: HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatography-tandem mass spectrometry; CL int, in vitro , in vitro intrinsic clearance observed when test compounds were metabolized by human hepatocytes suspended in human serum; D, cell density of hepatocytes suspended in serum; T, incubation time; R, ratio of intact drug concentration after incubation to that at time 0; SF 70ϩ73 , scaling factor calculated from CL int, in vitro, 70ϩ73 /CL H, int, in vivo for the pooled hepatocyte preparation of lot 70 and 73; CL H, int, in vitro, 70ϩ73 , hepatic intrinsic clearance calculated from in vitro data using the pooled hepatocyte preparation of lot 70 and 73; CL int, in vitro, 70ϩ73 , in vitro intrinsic clearance observed when test compounds were metabolized in the pooled hepatocyte preparation of lot 70 and 73 suspended in human serum; F H , hepatic availability; CL H, predicted, 70ϩ73 , predicted hepatic clearance from CL int, in vitro, 70ϩ73 and average SF 70ϩ73 ; Q H , hepatic blood flow rate; R B , blood-to-plasma concentration ratio; D N , dispersion number; CL P, in vivo , in vivo plasma clearance; F PO, in vivo , oral bioavailability in humans; CL H, int, in vivo , hepatic intrinsic clearance calculated from F PO, in vivo by the dispersion model (using the Goal Seek method attached to Microsoft Excel); SF mean , mean of scaling factor calculated from CL int, in vitro, mean/CL H, int, in vivo for 10 individual lots; average SF mean , average value of SF mean for seven standard compounds; F H, predicted, 70ϩ73 , predicted hepatic availability from CL int, in vitro, 70ϩ73 and average SF 70ϩ73 ; SF biol , biologically based scaling factor of hepatocellularity (3.1ϫ10 9 cells/kg); average SF 70ϩ73 , average value of SF 70ϩ73 for seven standard compounds.
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All these values were quoted from the literature as follows. Naloxone [Asali and Brown (1984) ; Holford (1998) ]; buspirone [Gammans et al. (1986) ]; verapamil [Gross et al. (1988); McAllister and Kirsten (1982) ; Obach (1999) ]; lidocaine; [Wing et al. (1984) , Remmel et al. (1991) ]; imipramine [the pharmacokinetics were mean value of the report of Nagy and Johansson (1975) and Ciraulo et al. (1988) ]; metoprolol ; Regardh et al. (1974) ; Regardh et al. (1981) ]; timolol [Wilson et al. (1982) , [Holford (1998] 
Profiles of 14 compounds tested with the pooled preparation of human hepatocytes lot 70 and 73 and the key parameters for the in vivo prediction
All these values were quoted from the literature as follows. Naloxone [Asali and Brown (1984) ; Holford (1998) ]; buspirone [Gammans et al. (1986) ]; verapamil [Gross et al. (1988); McAllister and Kirsten (1982) ; Obach (1999) ]; lidocaine [Remmel et al. (1991) ; Wing et al. (1984) ]; imipramine [the pharmacokinetics were mean value of the report of Ciraulo et al. (1988) and Nagy and Johansson (1975) ]; metoprolol ; Regardh et al. (1974) ; Regardh et al. (1981) ]; timolol [Wilson et al. (1982) , Holford (1998) ]; antipyrine [Elfstrom and Lindgren (1978) ; Vesell et al. (1975) ]; diazepam [Divoll et al. (1983) ; Greenblatt et al. (1980) ; Maguire et al. (1980) ]; quinidine [Guentert et al. (1979) ; Hardy and Schentag (1988) ; Hughes et al. (1975) ]; caffeine [Blanchard (1982) ; Newton et al. (1981) ]; propranolol [Walle et al. (1989) ; Wilson et al. (1982) ]; diclofenac [Chan et al. (1987); Obach (1999) ; Willis et al. (1980) ]; phenacetin [Raaflaub and Dubach (1975); Vesell et al. (1975)] .
No. (Iwatsubo et al., 1997) , and an average human has 1800 g of liver (Davies and Morris, 1993) ] was used to extrapolate CL int, in vitro to CL H, int, in vivo (Fig. 1) . Mean values for the empirical scaling factor (SF mean ) were calculated by averaging the ratio of CL H, int, in vivo to the corresponding in vitro values (CL int, in vitro ) for each standard compound (Table 1 ). The average SF mean value among seven standard compounds was found to be 8.5 ϫ 10 9 cells/kg, which was approximately 3 times larger than that of biologically based value (3.1 ϫ 10 9 cells/kg). Reasonably accurate predictions were achieved (Table 1; Fig. 1 ) when the scaling factors, thus empirically obtained, were used for the extrapolation.
The averaged results from 10 or more preparations of human hepatocytes appeared to provide more reliable predictions for the human liver metabolism, whereas it was less convenient and costeffective. It was found that the pooled preparation of two lots (lot 70 and 73) achieved the same extent of predictability for all seven standard compounds as the averaged results from 10 individual preparations (Tables 1 and 2 ). Pooled preparation demonstrated that the metabolic activity was constant during a 2-h incubation time period for standard compounds (Fig. 2) . The in vitro-in vivo-correlation study was further extended to another seven compounds by using pooled cryopreserved preparation of human hepatocytes ( Table 2 ). The predictions of CL H, predicted, 70ϩ73 and F H, predicted, 70ϩ73 were carried out with the average value of scaling factor (average SF 70ϩ73 , 10.8 ϫ 10 9 cells/kg) for total 14 compounds, which was obtained empirically as described for 7 standard compounds in the pooled hepatocyte preparation of lot 70 and 73. Reasonably good correlations were obtained for both oral bioavailability (Fig. 3, panel A) and hepatic clearance (Fig. 3, panel B) . These data demonstrated that the in vitro metabolic clearance obtained in the pooled preparation from cryopreserved human hepatocytes reasonably well predicted in vivo hepatic clearance and availability with the aid of empirical scaling factor.
Discussion
Isolated hepatocytes have been recognized as more in vivo relevant in vitro systems than the subcellular fractions such as liver S-9 and microsomes for the prediction of in vivo metabolism. Although the freshly isolated human hepatocytes appeared to be one of the best preparations for the prediction of in vivo metabolism in humans (Lavé et al., 1999) , the cryopreserved human hepatocytes instead became more prevalent and widely used for the routine analysis (Li, 2001) . Cryopreserved human hepatocytes have been reported to quantitatively retain most of the phase I metabolic activities observed in the fresh liver, whereas some phase II metabolic activities to certain substrates were lower in the cryopreserved preparation than the intact human liver (Li et al., 1999; Steinberg et al., 1999; Hengstler et al., 2000; Rialland et al., 2000) . In addition, consistent with the fact that each drug metabolizing enzyme activity in the human liver is known to individually vary between subjects, an approximately 3-to 5-fold variation was found in the in vitro metabolic clearance for the standard compounds among preparations from different human subjects (Table 1 ; Fig. 1 ). The interindividual variation in the metabolic capacity in the liver appears to reflect the observed large variation in the clearance in humans.
The empirical scaling factors for the in vitro-to-in vivo extrapolation (8.5 ϫ 10 9 cells/kg from 10 individual preparations in Table 1 ; 10.8 ϫ 10 9 cells/kg from pooled preparation in Table 2 ) were approximately 3 to 4 times larger than the anatomically calculated value (3.1 ϫ 10 9 cells/kg). In addition, the variation of scaling factor obtained from 10 individual preparations (SF mean in Table 1 ) between different compounds was much larger than that obtained from the pooled-cryopreserved preparation of human hepatocytes (SF 70ϩ73 in Table 2 ). These data suggested that the empirical scaling factor applicable only to the preparation used in the prediction was critically important for more reliable and rational predictions, which might compensate the inherent interindividual variation and/or loss of metabolic activities among different cryopreserved preparations.
In summary, the present study demonstrates that the direct evaluation of metabolic clearance in cryopreserved human hepatocytes in the presence of human serum was a convenient and useful tool for the prediction of hepatic clearance and availability. The calibration paradigm described in this report minimized the interindividual variation FIG. 1. CL H, int, in vivo versus CL int, in vitro Each symbol represents the mean of three determinations. The numbers correspond to the compound numbers listed in Table 1 .
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